Managing Fertility Evaluations

---
name: managing-fertility-evaluations
description: Structures infertility workup with ovarian reserve testing, semen analysis, and treatment algorithms. Use when evaluating infertility, ordering fertility workup, or managing reproductive planning.
tags:
  - management
  - obstetrics-and-gynecology
  - treatment
metadata:
  author: casemark
  practice_areas:
    - Obstetrics
    - Gynecology
    - Maternal-Fetal Medicine
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Fertility Evaluations

Structures infertility workup with ovarian reserve testing, semen analysis, tubal assessment, and stepped treatment algorithms per ASRM and ACOG Practice Bulletin No. 217.

## Why This Skill Exists

Infertility — defined as failure to conceive after 12 months of unprotected intercourse (or 6 months if female partner is ≥ 35) — affects approximately 12–15% of couples. The American Society for Reproductive Medicine (ASRM) recommends a systematic, simultaneous evaluation of both partners, as male factor contributes to approximately 40–50% of infertility cases (sole male factor ~20%, combined male + female ~20–30%). Delays in evaluation lead to age-related decline in ovarian reserve, diminishing treatment success.

ACOG Practice Bulletin No. 217 (Infertility Workup for the Women's Health Specialist) outlines the standard evaluation components. This skill ensures a complete, concurrent evaluation of ovulatory function, tubal patency, uterine anatomy, ovarian reserve, and male factor — then maps findings to the appropriate treatment tier.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. **Duration of infertility** — months of unprotected intercourse? Primary (never conceived) or secondary (prior pregnancy)? (Default: from history)
2. **Female partner age** — critical for prognosis and urgency of evaluation. (Default: from demographics)
3. **Coital frequency and timing** — intercourse frequency and relationship to ovulation? Use of ovulation prediction kits? (Default: from history)
4. **Menstrual history** — cycle length, regularity, signs of ovulatory dysfunction (oligomenorrhea, amenorrhea)? (Default: from menstrual calendar)
5. **Obstetric and gynecologic history** — prior pregnancies (with any partner), ectopic, PID, endometriosis, uterine surgery? (Default: from history)
6. **Male partner history** — prior paternity, testicular surgery, varicocele, medications, toxin exposure, ejaculatory dysfunction? (Default: from male partner history)
7. **Medical comorbidities** — thyroid disease, PCOS, hyperprolactinemia, DM, eating disorders, excessive exercise? (Default: from problem list)
8. **Social factors** — tobacco, alcohol, marijuana, occupation, environmental exposures? (Default: from social history)

### Documents to Request

- Prior fertility evaluation results (both partners)
- Semen analysis report(s)
- HSG or SHG reports
- Ovarian reserve testing (AMH, day-3 FSH/estradiol, antral follicle count)
- Thyroid function tests
- Prolactin level
- Prior operative reports (laparoscopy, hysteroscopy, tubal surgery)
- Genetic testing results (karyotype, FMR1, carrier screening)
- Partner medical records if available

---

## Step 1: Ovulatory Assessment

Ovulatory dysfunction accounts for approximately 25–30% of female infertility.

| Assessment Method | Timing | Interpretation |
|---|---|---|
| Menstrual history | Ongoing | Regular 24–35 day cycles strongly suggest ovulation |
| Basal body temperature (BBT) | Daily | Biphasic pattern (0.2–0.5°C rise) confirms ovulation retrospectively |
| Urine LH surge (OPK) | Mid-cycle | Positive predicts ovulation in ~24–36 hours |
| Mid-luteal progesterone | Day 21 (or 7 days post-expected ovulation) | > 3 ng/mL confirms ovulation |
| Endometrial biopsy | Luteal phase | No longer routinely recommended for dating; useful if endometrial pathology suspected |

### Ovulatory Dysfunction Workup

| Condition | Testing | Findings |
|---|---|---|
| PCOS | Rotterdam criteria: 2 of 3 — oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology on US | Elevated free testosterone, DHEA-S; LH:FSH ratio > 2:1 (supportive but not required) |
| Hypothalamic amenorrhea | FSH, LH, estradiol | Low/normal FSH, low LH, low estradiol |
| Hyperprolactinemia | Prolactin | > 25 ng/mL — repeat; if persistent, consider MRI pituitary |
| Thyroid dysfunction | TSH | Abnormal TSH → treat before fertility intervention |
| Premature ovarian insufficiency | FSH, AMH, estradiol | FSH > 40 IU/L (× 2 samples), low AMH, low estradiol |

---

## Step 2: Ovarian Reserve Assessment

Ovarian reserve predicts the quantity (not quality) of remaining oocytes and guides treatment intensity.

| Test | Timing | Normal Values | Interpretation |
|---|---|---|---|
| **AMH** (anti-Müllerian hormone) | Any cycle day | 1.0–3.5 ng/mL | < 1.0 = diminished reserve; > 3.5 = possible PCOS |
| **Day 3 FSH** | Cycle day 2–4 | < 10 IU/L | > 10 = diminished reserve; > 15 = poor prognosis |
| **Day 3 estradiol** | Cycle day 2–4 | < 80 pg/mL | Elevated E2 with normal FSH may mask diminished reserve |
| **Antral follicle count (AFC)** | Cycle day 2–5 (TVUS) | 10–20 total | < 5–7 = diminished reserve; > 20 = high responder / PCOS risk |

Combine AMH + AFC for the most accurate reserve assessment. Document results with age-adjusted interpretation.

---

## Step 3: Tubal and Uterine Evaluation

| Test | What It Assesses | Findings |
|---|---|---|
| **Hysterosalpingogram (HSG)** | Tubal patency, uterine cavity contour | Bilateral spill = patent tubes; filling defects = polyps/fibroids/synechiae; proximal vs. distal tubal occlusion |
| **Saline infusion sonohysterogram (SIS)** | Uterine cavity detail | Polyps, submucosal fibroids, Asherman syndrome |
| **Hysteroscopy** | Direct cavity visualization | Gold standard for intracavitary pathology — see and treat |
| **Laparoscopy with chromopertubation** | Tubal patency + peritoneal disease | Reserve for suspected endometriosis, PID, or equivocal HSG |

Uterine anomalies affecting fertility:
- **Septate uterus** — most common anomaly associated with pregnancy loss; hysteroscopic septum resection improves outcomes
- **Unicornuate uterus** — reduced cavity volume, associated with preterm delivery
- **Asherman syndrome** — intrauterine adhesions from prior instrumentation; hysteroscopic lysis

---

## Step 4: Male Factor Evaluation

Semen analysis is the cornerstone of male factor assessment. Per WHO 6th edition (2021) reference values:

| Parameter | Lower Reference Limit (5th percentile) |
|---|---|
| Volume | ≥ 1.4 mL |
| Sperm concentration | ≥ 16 million/mL |
| Total sperm count | ≥ 39 million per ejaculate |
| Progressive motility | ≥ 30% |
| Total motility | ≥ 42% |
| Normal morphology (strict Kruger) | ≥ 4% |

- Abnormal semen analysis → repeat in 4–12 weeks (values fluctuate)
- Persistently abnormal → urology referral for evaluation (hormonal — FSH, testosterone, prolactin; physical exam — varicocele; genetic — Y-microdeletion, karyotype if severe oligospermia < 5 million/mL)
- Azoospermia → obstructive vs. non-obstructive classification; refer to reproductive urologist

---

## Step 5: Treatment Algorithm

| Diagnosis | First-Line Treatment | Second-Line | Third-Line |
|---|---|---|---|
| **Ovulatory dysfunction (PCOS)** | Letrozole 2.5–7.5 mg CD 3–7 (superior to clomiphene per NICHD trial) | Clomiphene 50–150 mg CD 5–9; gonadotropins | IVF |
| **Unexplained infertility** | Timed intercourse × 3–6 cycles → letrozole/clomiphene + IUI × 3 | Gonadotropins + IUI (up to 3 cycles) | IVF |
| **Tubal factor (bilateral occlusion)** | IVF (bypass tubal disease) | Tubal surgery (selected cases with mild distal disease) | — |
| **Male factor (mild-moderate)** | IUI with sperm wash (requires ≥ 5–10 million TMSC) | IVF | IVF-ICSI |
| **Male factor (severe / azoospermia)** | IVF-ICSI with TESE/micro-TESE if needed | Donor sperm | — |
| **Diminished ovarian reserve** | Aggressive stimulation → IVF | Donor oocytes | — |
| **Endometriosis** | Surgical excision + spontaneous attempt × 6 months | IUI with controlled stimulation | IVF |

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. **Are both partners evaluated** — ovulatory function, tubal patency, ovarian reserve, and semen analysis all addressed?
2. **Is ovarian reserve documented** with age-adjusted interpretation?
3. **Is the treatment recommendation matched** to the specific diagnosis?
4. **Are time-sensitive factors addressed** — female age, duration of infertility, and declining reserve?
5. **Is the referral to reproductive endocrinology documented** when indicated (e.g., bilateral tubal disease, DOR, severe male factor)?

---

## Quality Audit

- [ ] Duration and type (primary vs. secondary) of infertility documented
- [ ] Female partner age documented with prognostic implications noted
- [ ] Ovulatory assessment completed (menstrual history + mid-luteal progesterone or OPK)
- [ ] Ovarian reserve testing documented (AMH + AFC or day-3 FSH/E2)
- [ ] TSH and prolactin documented
- [ ] HSG or SIS performed and results documented
- [ ] Semen analysis performed with WHO 6th edition reference values applied
- [ ] Abnormal semen analysis repeated and/or urology referral documented
- [ ] Uterine cavity evaluation completed
- [ ] PCOS evaluation documented using Rotterdam criteria (if oligoovulation present)
- [ ] Treatment plan documented with tier-appropriate recommendation
- [ ] Genetic screening offered (carrier screening per ACOG, karyotype if indicated)
- [ ] Pre-conception counseling documented (folate, weight optimization, substance cessation)
- [ ] Timeline for treatment escalation documented

---

## Guidelines

1. **Evaluate both partners simultaneously** — do not complete the full female workup before ordering a semen analysis; male factor is present in 40–50% of cases.
2. **Age drives urgency** — women ≥ 35 should be referred after 6 months; women ≥ 40 warrant immediate evaluation.
3. **Letrozole is first-line for PCOS ovulation induction** — the NICHD PPCOS II trial demonstrated higher live birth rates with letrozole vs. clomiphene.
4. **Do not skip ovarian reserve testing** — even in young patients, diminished reserve changes the treatment approach and timeline.
5. **Document the AFC method** — report bilateral antral follicle count with probe frequency and technique for reproducibility.
6. **Recognize when to refer** — bilateral tubal occlusion, severe male factor, diminished ovarian reserve, and age ≥ 38 with > 6 months of failed first-line treatment should be referred to a reproductive endocrinologist.
7. **Counsel on realistic expectations** — per-cycle success rates for IUI are 10–20%, and IVF success rates are age-dependent (age < 35: ~50% live birth per transfer; age 40–42: ~15%).
8. **Address lifestyle factors** — BMI optimization (ideal 19–25), smoking cessation, alcohol limitation, and caffeine < 200 mg/day all impact fertility.